Simparica Trio for Dogs: Comprehensive Parasite Prevention

Simparica Trio (sarolaner, moxidectin, and pyrantel pamoate chewable tablets) represents a significant advancement in canine parasitology, offering broad-spectrum protection against ectoparasites (fleas and ticks), heartworm (Dirofilaria immitis), and intestinal nematodes in a single monthly oral formulation. As the landscape of veterinary parasitology evolves with emerging drug resistance and new combination products, understanding the clinical position of Simparica Trio is essential for both practitioners and dedicated pet owners. This article provides an exhaustive, evidence-based review of Simparica Trio, integrating the latest peer-reviewed research, international guidelines, and practical clinical considerations.

Quick Q&A

Question: What makes Simparica Trio different from other monthly parasite preventatives for dogs?

Answer: Simparica Trio is unique because it combines three active ingredients (sarolaner, moxidectin, and pyrantel) in one chewable tablet to protect against fleas, ticks, heartworm, and intestinal worms (roundworms and hookworms). Unlike some products that require separate applications, Simparica Trio provides comprehensive coverage in a single monthly dose, with demonstrated efficacy against drug-resistant parasites and rapid speed of kill against ticks.

Introduction: The Need for Comprehensive Parasite Control

Parasitic infections in dogs remain a global veterinary and public health concern. Fleas (Ctenocephalides felis and C. canis), ticks (including Ixodes scapularis, Rhipicephalus sanguineus, and Haemaphysalis longicornis), heartworm, and intestinal nematodes (roundworms Toxocara canis, Toxascaris leonina, and hookworms Ancylostoma caninum) cause significant morbidity and can transmit zoonotic diseases. The American Animal Hospital Association (AAHA) and the Companion Animal Parasite Council (CAPC) recommend year-round, broad-spectrum parasite prevention for all dogs, regardless of geographic location or lifestyle.

Simparica Trio, developed by Zoetis, was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a monthly oral chewable tablet. It combines three active ingredients: sarolaner (an isoxazoline ectoparasiticide), moxidectin (a macrocyclic lactone endectocide), and pyrantel pamoate (a tetrahydropyrimidine anthelmintic). This triple-action formulation addresses the major parasitic threats in a single dose, improving compliance compared to multi-product regimens.

Clinical Pharmacology and Mechanism of Action

Sarolaner: The Isoxazoline Ectoparasiticide

Sarolaner is a member of the isoxazoline class, which acts as a potent antagonist of gamma-aminobutyric acid (GABA)-gated chloride channels and, to a lesser extent, glutamate-gated chloride channels in invertebrates. This leads to hyperexcitation of the parasite's nervous system, resulting in rapid paralysis and death. Isoxazolines are highly selective for insect and acarine GABA receptors over mammalian receptors, providing a wide safety margin [40]. Sarolaner is rapidly absorbed after oral administration, reaching peak plasma concentrations within 2-4 hours, and provides sustained activity against fleas and ticks for at least 35 days.

Moxidectin: The Macrocyclic Lactone for Heartworm and Endoparasites

Moxidectin is a second-generation macrocyclic lactone that binds to glutamate-gated chloride channels in nematodes and arthropods, causing flaccid paralysis and death. It is highly lipophilic, leading to a longer half-life and persistent tissue levels compared to ivermectin. Moxidectin is effective against Dirofilaria immitis (heartworm) larvae (L3 and L4 stages), as well as Ancylostoma caninum and Toxocara canis. Importantly, moxidectin has demonstrated efficacy against macrocyclic lactone-resistant isolates of D. immitis [7] and plays a role in adulticide protocols for heartworm disease [9].

Pyrantel Pamoate: The Nicotinic Anthelmintic

Pyrantel pamoate is a depolarizing neuromuscular blocking agent that acts as a cholinergic agonist at nicotinic acetylcholine receptors in nematodes. It causes spastic paralysis and expulsion of adult roundworms (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala). Pyrantel has a wide safety margin and is poorly absorbed systemically, acting primarily within the gastrointestinal tract.

Clinical Efficacy: Evidence from Recent Research

Speed of Kill Against Ticks

Rapid speed of kill is critical for reducing the risk of tick-borne disease transmission. A 2026 study by Reif et al. compared the speed of kill of Simparica Trio (sarolaner) against Ixodes scapularis with other endectocides, including afoxolaner (NexGard PLUS) and lotilaner (Credelio Quattro). Simparica Trio demonstrated >95% efficacy within 8 hours of infestation, with sustained protection for the full month [1]. Similarly, Van Brussel and Geurden (2026) evaluated Simparica Trio against Ixodes ricinus in dogs and confirmed rapid killing within 12 hours, significantly reducing the window for Borrelia burgdorferi transmission [4].

Efficacy Against Drug-Resistant Heartworm

Macrocyclic lactone resistance in Dirofilaria immitis is a growing concern, particularly in the Mississippi River Delta region of the United States. A pivotal 2026 study by Rodriguez et al. compared six monthly doses of Simparica Trio against a macrocyclic lactone-resistant D. immitis isolate (JYD-34). Simparica Trio provided 100% prevention of heartworm infection, outperforming NexGard PLUS in the same study [7]. This finding is clinically significant, as it positions moxidectin (at the dose in Simparica Trio) as a robust option in regions where resistance has been documented.

Efficacy Against Multidrug-Resistant Hookworms

Hookworm resistance, particularly Ancylostoma caninum resistance to multiple anthelmintic classes (benzimidazoles, macrocyclic lactones, and pyrantel), has emerged as a major clinical challenge [2, 5, 38]. The American Association of Veterinary Parasitologists (AAVP) Hookworm Task Force has published best practices for diagnosis and treatment, emphasizing the need for combination therapy [5]. Simparica Trio, containing both moxidectin and pyrantel, provides a dual mechanism of action against hookworms. While pyrantel resistance has been reported, the addition of moxidectin may improve efficacy against resistant populations. However, veterinarians should remain vigilant and consider fecal egg count reduction tests in cases of suspected resistance.

Efficacy Against Emerging Tick Species

The Asian longhorned tick (Haemaphysalis longicornis) has rapidly expanded its range in the United States since its initial detection in 2017. Rodriguez et al. (2026) demonstrated that Simparica Trio is highly effective against two U.S. strains of H. longicornis, with >98% efficacy within 24 hours of infestation [23]. This is particularly important for practitioners in the eastern U.S., where this tick species is now established.

Prevention of Borrelia burgdorferi Transmission

Lyme disease (Borrelia burgdorferi) is a significant tick-borne zoonosis. Geurden et al. (2026) demonstrated that Simparica Trio, by rapidly killing Ixodes scapularis (the primary vector), prevents transmission of B. burgdorferi to dogs [14]. The study showed that dogs treated with Simparica Trio had significantly lower seroconversion rates compared to untreated controls, supporting its role in Lyme disease prevention.

Efficacy Against Dipylidium caninum Transmission

Fleas serve as intermediate hosts for the tapeworm Dipylidium caninum. A 2025 study by Weaver et al. confirmed that Simparica Trio kills Ctenocephalides felis on dogs before the flea can transmit D. caninum cysticercoids, providing month-long protection against this common tapeworm [28].

Treatment of Angiostrongylus vasorum

Angiostrongylus vasorum (French heartworm) is an emerging cardiopulmonary nematode in dogs, particularly in Europe and parts of North America. Lloyd et al. (2026) assessed the safety and efficacy of Simparica Trio in treating naturally infected dogs. The study demonstrated that a single dose of Simparica Trio significantly reduced larval counts and improved clinical signs, positioning it as a treatment option for this potentially fatal infection [29].

Safety Profile and Adverse Effects

General Safety

Simparica Trio has been extensively evaluated in laboratory and field studies. The most common adverse events reported in clinical trials are mild and self-limiting, including vomiting, diarrhea (or diarrhoea), lethargy, anorexia, and pruritus. In a large field study, the incidence of vomiting was approximately 5-7%, with most cases occurring within 24 hours of dosing and resolving without intervention.

Neurological Safety and the MDR1 Gene

Isoxazolines, including sarolaner, have been associated with neurological adverse events (e.g., tremors, ataxia, seizures) in some dogs, particularly those with a history of seizures or epilepsy. The product label warns against use in dogs with a history of seizures. However, a 2025 comparative study by Sager et al. found that sarolaner has a lower affinity for mammalian GABA receptors compared to some other isoxazolines, potentially reducing the risk of neurological effects [40].

Macrocyclic lactones (including moxidectin) are substrates for P-glycoprotein (P-gp), encoded by the MDR1 gene (also known as ABCB1). Dogs with the MDR1 mutation (common in Collies, Australian Shepherds, and other herding breeds) are at increased risk for neurotoxicity from macrocyclic lactones due to reduced efflux from the brain. However, the dose of moxidectin in Simparica Trio is considered safe for MDR1 mutant dogs when used according to label directions. A 2026 study by Burke and Mealey validated a flow cytometric assay for assessing P-gp substrate specificity, confirming that moxidectin is a moderate P-gp substrate [15]. Nonetheless, veterinarians should exercise caution and consider baseline neurological assessment in at-risk breeds.

Long-Term Safety

Long-term safety data for combination products are reassuring. A 2025 study by Riggs et al. evaluated the long-term safety of Credelio Quattro (a similar combination product containing lotilaner, moxidectin, pyrantel, and praziquantel) and found no significant adverse effects over 12 months of monthly dosing [26]. While this study did not evaluate Simparica Trio specifically, the shared components (moxidectin and pyrantel) suggest a comparable safety profile.

Environmental Considerations

A 2026 study by Berny et al. raised concerns about prolonged fecal elimination of isoxazoline drugs in dogs and cats, potentially posing a risk to non-target species (e.g., dung beetles, aquatic invertebrates) [22]. While the clinical significance for individual pets is minimal, veterinarians should be aware of this emerging environmental discussion and counsel clients on responsible disposal of pet waste.

Comparison with Other Preventatives

Simparica Trio vs. NexGard PLUS (Afoxolaner, Moxidectin, Pyrantel)

NexGard PLUS is a direct competitor to Simparica Trio, containing afoxolaner (isoxazoline) instead of sarolaner. Both products provide identical coverage against heartworm, intestinal nematodes, fleas, and ticks. Key differences include:

• Speed of kill: Simparica Trio (sarolaner) has demonstrated faster speed of kill against Ixodes scapularis compared to NexGard PLUS (afoxolaner) in some studies [1].
• Heartworm resistance: Simparica Trio showed superior efficacy against a macrocyclic lactone-resistant D. immitis isolate in a head-to-head study [7].
• Tick spectrum: Both products are effective against Ixodes, Rhipicephalus, Dermacentor, and Amblyomma species. Simparica Trio has published data against Haemaphysalis longicornis [23]; NexGard PLUS has data against Amblyomma maculatum [25].

Simparica Trio vs. Credelio Quattro (Lotilaner, Moxidectin, Pyrantel, Praziquantel)

Credelio Quattro adds praziquantel (for tapeworms) to the combination, making it a more comprehensive option for cestode control. However, Simparica Trio has demonstrated efficacy against Dipylidium caninum transmission via flea control [28], whereas Credelio Quattro directly treats tapeworm infections. The choice between these products may depend on regional cestode prevalence and client preference.

Simparica Trio vs. BRAVECTO TriUNO (Fluralaner, Moxidectin, Pyrantel)

BRAVECTO TriUNO contains fluralaner (a long-acting isoxazoline) and provides 12 weeks of flea and tick protection per dose, compared to Simparica Trio's monthly dosing. Both products contain moxidectin and pyrantel for heartworm and intestinal nematodes. BRAVECTO TriUNO may be preferred for clients seeking less frequent dosing, while Simparica Trio offers monthly administration, which some owners find easier to remember.

Simparica Trio vs. Topical Products (e.g., Revolution Plus, Advantage Multi)

Topical products containing selamectin or moxidectin offer similar endectocide coverage but may be preferred for dogs that are difficult to pill or have a history of gastrointestinal sensitivity. However, topical products can be affected by bathing, swimming, and coat condition, whereas oral products like Simparica Trio provide consistent systemic exposure.

Regional Considerations and Guidelines

United States

The CAPC recommends year-round heartworm prevention and broad-spectrum parasite control. Simparica Trio is approved for use in dogs and puppies 8 weeks of age and older, weighing at least 2.8 lbs (1.25 kg). It is important to test for heartworm antigen and microfilariae before initiating prevention, as moxidectin can cause a severe anaphylactic reaction (shock-like syndrome) in microfilaremic dogs.

Canada

The Canadian Veterinary Medical Association (CVMA) and the Canadian Parasitology Expert Panel endorse year-round prevention. Simparica Trio is available in Canada and is particularly useful in regions where Ixodes scapularis (Lyme disease vector) and Dirofilaria immitis are endemic (e.g., southern Ontario, Quebec, and British Columbia).

Europe

The European Scientific Counsel for Companion Animal Parasites (ESCCAP) provides guidelines for parasite control across Europe. Simparica Trio is registered in the EU and is recommended for dogs traveling within the Pet Travel Scheme (PETS), as it covers ticks and heartworm (in endemic areas). In the UK, where heartworm is not endemic, the product is primarily used for flea, tick, and intestinal worm control. ESCCAP emphasizes the importance of treating for tapeworms in dogs that hunt or scavenge, which may require an additional praziquantel product.

Australia

The Australian Veterinary Association (AVA) and the Australian Parasitology Society recommend year-round heartworm prevention, particularly in northern and coastal regions. Simparica Trio is registered in Australia and is effective against the brown dog tick (Rhipicephalus sanguineus) and the paralysis tick (Ixodes holocyclus). However, veterinarians should note that Simparica Trio is not labeled for the prevention of paralysis tick (I. holocyclus) in Australia, and alternative products (e.g., fluralaner-based products) may be preferred in high-risk areas.

Clinical Use and Dosing

Simparica Trio is administered orally once a month, with or without food. The chewable tablets are flavored and generally well-accepted by dogs. The dose is based on body weight, with five tablet sizes available to accommodate dogs from 2.8 lbs to over 132 lbs.

Administration Tips

• Administer the tablet directly or hide it in a small amount of food.
• Ensure the entire dose is consumed; if vomiting occurs within 2 hours of dosing, re-dose.
• For dogs with a history of gastrointestinal sensitivity, consider administering with a small meal to reduce the risk of vomiting.

Missed Dose Protocol

If a dose is missed, administer Simparica Trio immediately and resume monthly dosing. For heartworm prevention, a missed dose increases the risk of breakthrough infection, particularly in high-risk areas. If more than 2 months have elapsed since the last dose, heartworm antigen testing should be performed before re-starting prevention.

Drug Interactions and Contraindications

Simparica Trio is contraindicated in dogs with a history of hypersensitivity to any of its components. It should be used with caution in dogs with a history of seizures, as isoxazolines have been associated with neurological adverse events. Concurrent use with other macrocyclic lactones (e.g., high-dose ivermectin for demodicosis) may increase the risk of neurotoxicity and should be avoided.

Simparica Trio can be used safely with most other medications, including vaccines, antibiotics, and non-steroidal anti-inflammatory drugs (NSAIDs). However, caution is advised when used concurrently with other P-gp substrates (e.g., loperamide, certain chemotherapeutic agents) in MDR1 mutant dogs.

Emerging Resistance and Future Directions

Macrocyclic Lactone Resistance

Resistance to macrocyclic lactones in Dirofilaria immitis and Ancylostoma caninum is an evolving threat. The 2026 AAVP Hookworm Task Force review emphasizes the importance of combination therapy to delay resistance [5]. Simparica Trio, with its dual-action against hookworms (moxidectin + pyrantel), represents a rational approach to resistance management. However, veterinarians should perform routine fecal examinations and fecal egg count reduction tests to monitor efficacy.

Isoxazoline Resistance

To date, no confirmed cases of isoxazoline resistance have been reported in fleas or ticks. However, the widespread use of this class warrants ongoing surveillance. A 2025 study by Sager et al. comparing isoxazoline activity on human and canine GABA receptors provides a foundation for understanding potential resistance mechanisms [40].

Novel Combination Products

The market for combination endectocides is expanding. Recent approvals include Credelio Quattro (lotilaner, moxidectin, pyrantel, praziquantel) and BRAVECTO TriUNO (fluralaner, moxidectin, pyrantel). These products offer similar coverage with varying ectoparasiticide components and dosing intervals. The choice between products should be individualized based on the dog's risk profile, owner compliance, and regional parasite prevalence.

Conclusion

Simparica Trio is a highly effective, well-tolerated, and convenient monthly oral combination product for comprehensive parasite prevention in dogs. Its triple-action formulation (sarolaner, moxidectin, pyrantel) provides protection against fleas, ticks, heartworm, and intestinal nematodes, with demonstrated efficacy against drug-resistant parasites and emerging tick species. Recent research confirms its rapid speed of kill against ticks, prevention of tick-borne disease transmission, and efficacy against macrocyclic lactone-resistant heartworm isolates.

Veterinarians should consider Simparica Trio as a first-line option for dogs requiring broad-spectrum parasite control, particularly in regions where resistance is a concern. As with all parasiticides, adherence to label directions, routine fecal monitoring, and heartworm testing are essential for optimal outcomes. The evolving landscape of antiparasitic resistance underscores the importance of evidence-based prescribing and the continued development of novel combination therapies.

References

1. Reif KE, Kollasch TM, Locklear CL, et al. Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio), afoxolaner (NexGard PLUS), or lotilaner (Credelio Quattro). Parasit Vectors. 2026.
2. McKean EL, Jackson CA, O'Halloran DM, et al. Association between macrocyclic lactone and benzimidazole resistance in the dog hookworm Ancylostoma caninum. J Parasitol. 2026.
3. Oladoye MJ, Awosile B, Adekoya O, et al. Patterns of antiparasitic usage in Golden Retriever breed of dogs: A 9-year cohort study. J Helminthol. 2026.
4. Van Brussel L, Geurden T. Evaluation of the speed-of-kill of Simparica Trio against Ixodes ricinus in dogs. Ticks Tick Borne Dis. 2026.
5. Kaplan RM, Jimenez Castro PD, Marsh AE, et al. American Association of Veterinary Parasitologists Hookworm Task Force review on best practices for diagnosis and treatment of multidrug-resistant hookworms. J Am Vet Med Assoc. 2026.
6. Genchi M, Venco L, Fozzer M, et al. Efficacy and safety of a sustained-release formulation of ivermectin (FILAPREV) in preventing heartworm infection (Dirofilaria immitis) in dogs in two endemic areas of Italy. Parasit Vectors. 2026.
7. Rodriguez J, Jones S, Mahabir S, et al. Comparative efficacy of six monthly doses of Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) versus NexGard Plus (afoxolaner, moxidectin, and pyrantel chewable tablets) against a macrocyclic lactone-resistant Dirofilaria immitis isolate in dogs. Parasit Vectors. 2026.
8. Young L, Wang X, Wiseman S, et al. Efficacy of Credelio Quattro chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs. Parasit Vectors. 2026.
9. Santiwattanatarm T, Sakcamduang W, Kongkaew C, et al. A systematic review and meta-analysis of non-arsenical adulticide protocols using moxidectin and doxycycline for the treatment of adult heartworm infection in dogs. Curr Res Parasitol Vector Borne Dis. 2026.
10. Young L, Reinemeyer CR, Abdelmoneim M, et al. Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2026.
11. Bonfim IV, Cruz BC, Gatto IRH, et al. Efficacy of a short-acting oral fluralaner formulation (WellPet) against fleas and brown dog ticks in controlled and field conditions. Front Vet Sci. 2026.
12. Chiummo R, Zschiesche E, Kirkova Z, et al. Field study evaluating the efficacy of a combination formulation of fluralaner with moxidectin and pyrantel (BRAVECTO TriUNO) against canine intestinal nematode infections. Parasit Vectors. 2026.
13. Tielemans E, Sioutas G, Papadopoulos E. Field efficacy of a combination of afoxolaner, moxidectin and pyrantel pamoate against natural infestation with Otodectes cynotis in dogs. Parasite. 2026.
14. Geurden T, Holzmer S, Myers JAE, et al. Efficacy of Simparica and Simparica TRIO for the prevention of Borrelia burgdorferi by Ixodes scapularis. Parasit Vectors. 2026.
15. Burke NS, Mealey KL. Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates. Am J Vet Res. 2026.
16. Rajković M, Rajković V, Bogunović D. Dirofilaria immitis and Dirofilaria repens co-infection in a microfilaremic dog from Negotin, Eastern Serbia: Unusual localization of adult Dirofilaia repens in an abdominal hernia sac. Vet Parasitol Reg Stud Reports. 2026.
17. Cruz BC, Teixeira MB, de Melo Cruz GA, et al. Efficacy of a fluralaner-based ectoparasiticide for the control of otodectic and sarcoptic mange in naturally infested dogs, evaluated in randomized, double-blind clinical studies. Parasit Vectors. 2026.
18. Heinau L, Petersen I, Rohdich N, et al. Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTO TriUNO) against hookworm and Toxascaris leonina infections in a non-terminal study design in dogs. Parasit Vectors. 2026.
19. Martins AL, Mourão J, Amorim I, et al. Antiparasitic practices in Portuguese animal shelters: A survey of veterinarians. Res Vet Sci. 2026.
20. Antoine L, Papadopoulos E, Sioutas G, et al. Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei. Parasite. 2026.
21. Nogueira LLDC, Araújo BVS, Antunes JMAP, et al. Blood bronchial mucus with Dirofilaria immitis adult worms after the treatment with doxycycline and moxidectin: a rare case presentation. Parasitology. 2026.
22. Berny PJ, España B, Auré J, et al. Prolonged fecal elimination of isoxazoline antiparasitic drugs in dogs and cats: is there a risk for nontarget species? Environ Toxicol Chem. 2026.
23. Rodriguez J, Jones S, Taylor L, et al. Efficacy of sarolaner in Simparica (sarolaner) chewables and Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) against two US strains of Haemaphysalis longicornis. Parasit Vectors. 2026.
24. Siegl L, Bethäuser M, Nürnberger D, et al. Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany. J Vet Pharmacol Ther. 2026.
25. Prullage J, Shryock J, Dumont P, et al. Efficacy of oral afoxolaner and a combination of afoxolaner, moxidectin, and pyrantel against Amblyomma maculatum in dogs. Parasit Vectors. 2025.
26. Riggs KL, Wang X, Wiseman S. Long-term safety of Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs. Parasit Vectors. 2025.
27. Anderson W, Savadelis MD, Wiseman S, et al. Efficacy of Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio (lotilaner) chewable tablets in the prevention of Borrelia burgdorferi transmission from infected Ixodes scapularis in dogs. Parasit Vectors. 2025.
28. Weaver L, Viljoen A, Maree R, et al. Simparica Trio kills Ctenocephalides felis on dogs and provides month-long protection against the transmission of Dipylidium caninum. Parasit Vectors. 2025.
29. Lloyd A, Van Mechelen L, Van Overloop C, et al. Safety and efficacy assessment of a chewable tablet containing sarolaner, moxidectin, and pyrantel in the treatment of Angiostrongylus vasorum in dogs. Vet Parasitol. 2026.
30. Almendros A, Hobi S, You Z, et al. Unveiling Dirofilaria Asiatica infection: first clinical insights and treatment challenges for this feline zoonotic parasitosis. Vet Res Commun. 2025.
31. Humak F, Buono F, Veneziano V, et al. Field efficacy of Febantel, Pyrantel embonate and Praziquantel (Drontal Tasty) against naturally acquired intestinal helminths of hunting dogs in southern Italy. Parasit Vectors. 2025.
32. Quintana TA, Brewer MT, Jesudoss Chelladurai JRJ. Transcriptional responses to in vitro macrocyclic lactone exposure in Toxocara canis larvae using RNA-seq. Int J Parasitol Drugs Drug Resist. 2025.
33. Charles S, Wiseman S, Wang X, et al. Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel against Toxocara canis and Toxascaris leonina infections in dogs. Parasit Vectors. 2025.
34. Wiseman S, Savadelis MD, Maree R, et al. Efficacy of Credelio Quattro (lotilaner, moxidectin, pyrantel, praziquantel) and Credelio (lotilaner) against longhorned tick, Haemaphysalis longicornis,-induced infestations on dogs. Parasit Vectors. 2025.
35. Kéfer A, Machiels H, Vincken G, et al. Unusual Electrophoretic Pattern in a Dog Infected With Angiostrongylus vasorum. Vet Clin Pathol. 2025.
36. Charles S, Wiseman S, Savadelis MD, et al. Field efficacy and safety evaluation of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel against gastrointestinal nematode infections in dogs in the USA. Parasit Vectors. 2025.
37. Mitchell ND, Balk JD, Hughes J, et al. Eucoleus boehmi in dogs: Anthelmintic treatment challenges and impact on olfactory capacity. Vet Parasitol. 2025.
38. Geary TG, Drake J, Gilleard JS, et al. Multiple anthelmintic drug resistance in the canine hookworm Ancylostoma caninum: AAVP position paper and research needs. Vet Parasitol. 2025.
39. Currie BJ, Hoopes J, Cumming B. Cutaneous Larva Migrans Refractory to Therapy with Ivermectin: Case Report and Review of Implicated Zoonotic Pathogens, Epidemiology, Anthelmintic Drug Resistance and Therapy. Trop Med Infect Dis. 2025.
40. Sager H, Sarr A, Kuntz E, et al. Comparative analysis of isoxazoline activity on human and canine GABA receptors expressed in Xenopus oocytes. Parasit Vectors. 2025.